Revenue segments as reported by the company.

Online Revenue

Wholesale Revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing

Operations and support

Technology and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Hims & Hers Health

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Hims & Hers Health achieves record revenue and profitability growth

Hims & Hers Health shows strong financial performance with revenue growth and profitability milestones.
The company's focus on customer-centric strategies, brand building, and innovation drives growth.
Challenges include competition in new categories and maintaining margins on personalized products.
Opportunities lie in expanding product offerings, improving customer experience, and leveraging efficiencies.

Hims & Hers Health excels in Q1 earnings, eyes strategic growth

Hims & Hers Health delivered robust financial performance in Q1 2023, driven by revenue growth, improved margins, and disciplined expense management.
The company's strengths lie in its focus on trusted brands, innovation in product offerings, and commitment to clinical excellence, fostering consumer trust and loyalty.
While challenges like insurance reimbursement and new category entries exist, they present opportunities for strategic growth and market differentiation in the healthcare sector.

Hims & Hers Health (HIMS) reports robust Q2 earnings, eyes personalized healthcare growth

Hims & Hers Health delivered strong financial performance in Q2, driven by revenue growth, expanded gross margins, and operational efficiency. While facing short-term challenges from pricing investments, the company remains focused on long-term growth through personalized treatments and new category launches. Opportunities lie in leveraging consumer trends towards personalized healthcare and expanding product offerings.

Hims & Hers Health reports robust Q3 performance and growth opportunities

Hims & Hers Health (HIMS) showcased strong performance, innovation, and resilience in Q3, driving revenue growth, subscriber base expansion, and improved profitability.
While challenges like achieving positive net income and balancing growth with new category launches exist, the company's strategic initiatives and focus on customer value creation position it for future success.
Opportunities in the weight management category, personalized products, and efficiency gains present avenues for HIMS to capitalize on market trends and enhance its competitive edge.
With a solid financial position, a clear marketing strategy, and a commitment to customer engagement, HIMS is poised for continued growth and value creation in the healthcare sector.

Hims & Hers Health reports stellar Q4 performance and growth outlook

Hims & Hers Health delivered a strong performance in Q4 2023, with robust revenue growth, positive net income, and expanded gross margins.
The company's focus on personalized solutions, subscriber growth, and financial strength positions it well for future growth and market expansion.
While facing challenges in managing costs and margin expansion, HIMS has opportunities to drive revenue growth, enhance user experience, and offer a diverse product range.
By balancing its strengths, addressing challenges, and seizing opportunities, Hims & Hers Health is poised for continued success in the healthcare market.

Hims & Hers Health reports stellar Q1 results and eyes expansion

Hims & Hers Health's Q1 2024 performance reflects strong financial growth, driven by record subscriber numbers and revenue increase, underpinned by a strategic focus on personalized care and enhancing customer experience.
The company's strengths lie in their ability to drive consumer adoption through user-friendly solutions, capitalize on the rapid growth of the Hers segment, and maintain consumer confidence through strategic pricing initiatives.
While facing challenges in scaling operations and managing increased capital expenditures, HIMS has ample opportunities to expand their offerings, invest in new product categories, and drive further revenue growth through strategic pricing adjustments.

Hims & Hers Health posts stellar Q2 results, eyes revenue diversification

Hims & Hers Health (HIMS) reported impressive Q2 performance, with strong revenue growth and subscriber additions.
The company's strategic initiatives in weight management and sterile compounded medications position it for future success.
While facing challenges in data availability and market dynamics, Hims & Hers has opportunities for revenue diversification and enhanced customer engagement.

Hims & Hers Health (HIMS) reports stellar Q3 results and eyes growth through personalized healthcare

Hims & Hers Health's Q3 performance reflects strong revenue growth, subscriber expansion, and improved profitability, positioning the company for continued success.
While facing challenges in retention and operational efficiency, the company's strategic initiatives and market positioning offer opportunities for sustained growth and innovation.
With a focus on personalized healthcare solutions and social responsibility, Hims & Hers Health is well-positioned to capitalize on market opportunities and drive long-term value for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hims was founded in November 2017 after Andrew Dudum was called out by his sister for having dry skin and breakouts. After she ordered him expensive products to address his issues, Dudum realized that men don't have the same options as women when it comes to purchasing wellness products. 

Now with radiant skin, Andrew Dudum and Jack Abraham co-found HIMS as an Atomic (VC fund) portfolio company. The company initially sells hair loss treatments, biotin vitamins, shampoo, and erectile dysfunction treatments. 

The company raises $7 million in Series A from M/C Partners, SV Angel and Thrive Captial, putting its pre-money valuation at $13 million.

Hims raises $40 million in Series B led by IVP and Redpoint Ventures, putting its pre-money valuation at $160 million. 

Hims launches a women's brand, Hers. 

Hers offers telemedicine services, birth control, and non-prescription hair and skin-care products. 

The company partners with A-list couple Jennifer Lopez and Alex Rodriguez, who work with the company on the launch of new products. 

Hims raises $297 million in Series C funding led by DCM Ventures, NewView Capital, McKesson Ventures, putting its valuation at $1 billion.

Hims and Hers expands into virtual mental health services led by licensed professionals, with support groups available free of charge during the COVID-19 pandemic. 

The company now provides access to medical care and treatment for more than a dozen conditions with more than 50 products, and has facilitated 1 million medical visits through its telehealth platforms in 2019. 

Hims goes public through a merger with a blank-check company Oaktree Acquisition Corp at $1.6 billion valuation.

forhims.com/aboutus
forhims.com/investors
SEC
CNBC
Business Insider
Bloomberg
Crunchbase
Axios

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that Hims & Hers customers will now be able to supplement their treatment plan with daily meal replacement bars and shakes to support them on their comprehensive weight loss journey. Hims & Hers is elevating its offering to supplement the comprehensive, individualized weight management plans, designed by doctors, that take every aspect o.

Hims & Hers Expands Nutrition Support to Fuel Customers' Weight Loss Journeys

Hims & Hers Health can potentially face significant competition from Amazon's aggressive pricing and broad telehealth offerings, but its personalized care and strong financials offer resilience. Not every market Amazon has stepped into has been super disruptive, even if the market initially thought it would be. One example I mention is Amazon's Whole Foods acquisition. Hims & Hers' financials are robust, with strong and accelerating revenue growth, growing free cash flow, manageable SBC, and no debt.

Hims & Hers Health: Far From Dead, Even With Amazon's Threat Ahead

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS), the leading health and wellness platform, today announced Deb Autor, former deputy commissioner at the FDA, will join the company's board of directors, and Janet Stevens, a pharmaceutical quality expert, will join the company as Global Head of Quality & Safety. Hims & Hers continues to prioritize safety across its platform, offerings, and leadership so that every customer can have the confiden.

Hims & Hers Appoints Tenured Pharmaceutical, Regulatory, and Quality Experts to Key Leadership Positions

Hims & Hers has given back recent gains, but don't overlook the company's massive growth.

Hims & Hers Stock Is Down 30% This Week: Here's What Happened

Should You Buy Hims & Hers Stock on the Dip?

Hims & Hers stands out from Teladoc by focusing on direct-to-consumer telehealth services, contrasting Teladoc's business-to-business model. This telehealth company provides personalized treatments to select conditions like weight loss, hair loss, and sexual health. A reverse DCF analysis suggests its current stock price is more than justified.

Hims & Hers: Revolutionizing Telehealth And Captivating Investors - Here's Why You Should Buy

Hims & Hers Health, Inc.'s stock dropped over 25% over the last 2 days due to Amazon's entry into the hair loss and ED markets, but I believe investor pessimism is overblown. Despite Amazon's competition, Hims & Hers's focus on personalized solutions, which saw 175% YoY growth, provides a strong competitive moat. Even with conservative growth estimates, Hims & Hers has a 38% upside potential, maintaining my “buy” rating with a $27.5 price target.

Hims & Hers Health: The Amazon Curse Is Being Overstated

Amazon

Hims & Hers Health, a telehealth service for clients to access healthcare and prescriptions from home, is seeing its stock take a steep dive on Thursday, just after Amazon announced updates to a strikingly similar service for Prime members.

Hims & Hers stock tanks as Amazon debuts fixed pricing for hair-loss and erectile-dysfunction drugs

Amazon is now offering upfront pricing for virtual care for ailments such as men's hair loss and ED.

Hims & Hers' stock tumbles on Amazon's latest disruptive foray into healthcare

Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing for telehealth visits.

Amazon's push into telehealth knocks shares of Hims & Hers

Amazon announced Prime members can access new upfront pricing to treat five common conditions like erectile dysfunction and men's hair loss. The move places the company in competition with other direct-to-consumer marketplaces like Hims & Hers Health and Ro.

Amazon launches fixed pricing to treat conditions like hair loss. Hims & Hers stock drops 15%

Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's Wegovy.

Telehealth firm Hims & Hers launches weight-loss drug shortage tracker

HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.

Hims & Hers Stock Gains 31.1% Since Q3 Earnings: What's Next?

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today shared more data on the challenges Americans are facing when trying to access branded GLP-1 medication and introduced a GLP-1 Supply Tracker, where individuals can be a part of advocating for better access to the medications they need. Hims & Hers has been collecting data on access challenges across GLP-1s since the beginning of September. On just the.

Americans Continue to Struggle to Access Branded GLP-1s as Shortages Continue

The healthcare company is on fire, and it's still cheap by many measures.

Up 298% in a Year, Is Hims & Hers Health Still a Buy?

Astera Labs Inc

Payoneer Global

Every earnings season has its share of outperformers, companies that report blowout quarters and raise their forecasts. The market reacts quickly sending shares sharply higher.

3 Top Stocks Crushing Q3 Earnings With Strong 2024 Guidance

H&H's strong Q3 results signals a fundamental shift in the healthcare industry. GLP-1 drugs are certainly a growth catalyst for H&H but it is just a tiny component of the overall investment thesis. H&H investments in AI will drive massive efficiency gains while delivering immense value for providers and patients.

Hims & Hers: Undeservedly Undervalued

Hims & Hers is a rapidly emerging player in telehealth and wellness, catering to millennials and Gen Z. The company reported a 77% year-over-year revenue growth, with a subscriber base of 2 million. Hims & Hers' strategic marketing investments have led to positive net income, with potential for further growth and profitability.

Hims & Hers: A High-Growth Gem On The Verge Of Big Upside

Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Earnings Estimates Moving Higher for Hims & Hers Health (HIMS): Time to Buy?

Hims & Hers strong performance involves much more than just GLP-1 drugs.

After Another Blowout Quarter of Surging Revenue, Is Hims & Hers Stock a Once-in-a-Decade Buy?

The company expects to enjoy many GLP-1 tailwinds in 2025.

Missed Out on Eli Lilly? Buy This Amazing Growth Stock Instead

Most investors would look at an earnings announcement as a past event, connecting the current price action in the stock and reacting to the results as something that cannot be taken advantage of, thinking that it is now too late to get into action. This might be the case for shares of Hims & Hers Health Inc. NYSE: HIMS, as the stock is now rallying by over 6% the morning after the company reported its quarterly earnings.

Hims & Hers: Why This Healthcare Stock's Growth Makes It a Buy

Hims & Hers Health (HIMS) reported third-quarter results that topped analysts' expectations Monday, lifting its shares, as the company said t plans to release a generic version of a Novo Nordisk (NVO) diabetes and weight-loss drug as early as next year.

Hims Reports Strong Earnings, Novo Nordisk Copycat Drug Coming in 2025

Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial results. It rose by 2.5% to $21.27, 18.5% below its highest level this year.

Hims & Hers stock could dive soon despite strong results

Hims & Hers Health, Inc. reported record Q3 '24 revenues of over $400 million, beating estimates by nearly $19 million, and guided for up to 90% growth in Q4. The online health and wellness platform saw a 44% YoY subscriber growth, reaching 2 million subscribers, led by 175% growth in personalized services. Despite booming sales and strong financials, the stock remains undervalued, trading below 3x 2025 sales targets and only 22x updated adjusted EBITDA.

News for Hims & Hers Health Stock (HIMS)